RecruitingPhase 2NCT06911203

A Study of BGM0504 in Participants With Obesity

A Phase II, Randomized Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BGM0504 Compared to Tirzepatide in Adults Who Have Obesity

Sponsor

BrightGene Bio-Medical Technology Co., Ltd.

Enrollment

90 participants

Start Date

Apr 3, 2025

Study Type

INTERVENTIONAL

Conditions

Obesity

Summary

To evaluate the efficacy and safety of BGM0504 compared with Tirzepatide in adult participants who have obesity without diabetes after 26 weeks of treatment.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This Phase 2 study is comparing a new obesity medication called BGM0504 against Tirzepatide (an approved weight-loss drug) in adults with obesity but no diabetes. The goal is to see whether BGM0504 is as effective and safe as Tirzepatide after 26 weeks of treatment. Adults aged 18 to 65 with a BMI between 35 and 45 who have been managing their weight through diet and exercise for at least 3 months may be eligible. Participation involves receiving injections of the assigned medication and attending regular clinic visits for monitoring. This summary was prepared to help patients understand the study in plain language.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.